Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluating Impact of Azithromycin Mass Drug Administrations on Cause-specific Mortality and Antibiotic Resistance: Mortality Trial

Next Previous
Trial Profile

Evaluating Impact of Azithromycin Mass Drug Administrations on Cause-specific Mortality and Antibiotic Resistance: Mortality Trial

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azithromycin (Primary)
  • Indications Infections
  • Focus Therapeutic Use
  • Acronyms MORDOR; MORDORIMort

Most Recent Events

  • 26 May 2021 Results assessing the gut resistome of children after 5 years of biannual treatments published in the Clinical Infectious Diseases
  • 12 Nov 2020 Results investigating the gut resistome of children published in the New England Journal of Medicine
  • 01 Sep 2020 Results of subgroup analysis assessing mortality and drug distribution in malnourished children published in the PLOS Medicine.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top